CD56在肾细胞癌中的表达及其意义

目的研究CD56与肾细胞癌的细胞类型、肿瘤分级、临床分期及预后的关系。方法采用免疫组织化学二步法检测CD56在120例肾细胞癌中的表达,并对肾细胞癌组织进行系统的病理检查和分析。结果CD56的表达与肾细胞癌的病理分级和临床分期均呈正相关。CD56表达者与未表达者术后5年生存率分别为23.8%和92.5%,差异有统计学意义(P<0.05)。结论CD56的表达与肾细胞癌的病理分级和临床分期呈正相关,CD56与临床分期结合能更好地判断肾细胞癌的预后,CD56表达者易发生转移且预后差。

Expression of CD56 in renal cell carcinomas and its significance

Objective To investigate the relationship between CD56 expression and renal cell carcinomas. Method CD56 of 120 cases renal cell carcinomas was detected by immunohistochemistry. Result CD56 expression correlated with clinical phasing and pathological grading in renal cell carcinomas, the 5-year survival rate was significantly lower in CD56-positive group than that in CD56-negative group(23.8% vs 92.5%, P<0.05). Conclusions The CD56 can determine the degree of malignancy of renal cell carcinomas, and CD56 expression level connected with clinical phasing in renal cell carcinomas and can predict the prognosis. The cases with CD56 positive expression occur metastasis easy, and always have bad prognosis.